Document Detail

Tumours associated with BAP1 mutations.
MedLine Citation:
PMID:  23277170     Owner:  NLM     Status:  In-Data-Review    
SUMMARY: BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds to BRCA1. BAP1 is a tumour suppressor that is believed to mediate its effects through chromatin modulation, transcriptional regulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. Germline mutations of BAP1 confer increased susceptibility for the development of several tumours, including uveal melanoma, epithelioid atypical Spitz tumours, cutaneous melanoma, and mesothelioma. However, the complete tumour spectrum associated with germline BAP1 mutations is not yet known. Somatic BAP1 mutations are seen in cutaneous melanocytic tumours (epithelioid atypical Spitz tumours and melanoma), uveal melanoma, mesothelioma, clear cell renal cell carcinoma, and other tumours. Here, we review the current state of knowledge about the functional roles of BAP1, and summarise data on tumours associated with BAP1 mutations. Awareness of these tumours will help pathologists and clinicians to identify patients with a high likelihood of harbouring germline or somatic BAP1 mutations. We recommend that pathologists consider testing for BAP1 mutations in epithelioid atypical Spitz tumours and uveal melanomas, or when other BAP1-associated tumours occur in individual patients. Tumour tissues may be screened for BAP1 mutations/loss/inactivation by immunohistochemistry (IHC) (demonstrated by loss of nuclear staining in tumour cells). Confirmatory sequencing may be considered in tumours that exhibit BAP1 loss by IHC and in those with equivocal IHC results. If a BAP1 mutation is confirmed in a tumour, the patient's treating physician should be informed of the possibility of a BAP1 germline mutation, so they can consider whether genetic counselling and further testing of the patient and investigation of their family is appropriate. Recognition and evaluation of larger numbers of BAP1-associated tumours will also be necessary to facilitate identification of additional distinct clinico-pathological characteristics or other genotype-phenotype correlations that may have prognostic and management implications.
Rajmohan Murali; Thomas Wiesner; Richard A Scolyer
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pathology     Volume:  45     ISSN:  1465-3931     ISO Abbreviation:  Pathology     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0175411     Medline TA:  Pathology     Country:  England    
Other Details:
Languages:  eng     Pagination:  116-26     Citation Subset:  IM    
*Department of Pathology †Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA ‡Department of Dermatology, Medical University of Graz, Austria §Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital ||Discipline of Pathology, Sydney Medical School, The University of Sydney, Camperdown ¶Melanoma Institute Australia, North Sydney, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Frontline evaluation and treatment of patients with sinus disease: how otolaryngologists can help pr...
Next Document:  KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnosti...